CRISPR Therapeutics AG (CRSP)Healthcare | Biotechnology | Zug, Switzerland | NasdaqGM
57.72 USD
-1.65
(-2.779%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 57.50 -0.22 (-0.220%) ⇩ (Aug. 28, 2026, 7:52 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:46 a.m. EDT
The immediate outlook is driven by aggressive speculative positioning rather than fundamental recovery. While the company shows a recent price bounce and analysts maintain a 'Buy' rating, the underlying business remains in a precarious state with negative earnings, negative free cash flow, and a massive price-to-sales multiple of nearly 430x. The market is pricing in a potential clinical breakthrough or partnership deal, as evidenced by the heavy call buying at higher strikes, but the lack of dividends and ongoing cash burn leaves little room for error. The statistical forecasting model offers no directional guidance, highlighting the uncertainty surrounding the next catalyst. This is a high-risk, high-reward trade dependent entirely on future data releases rather than current operational performance. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.059720 |
| MSTL | 0.060017 |
| AutoTheta | 0.060199 |
| AutoETS | 0.060236 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.43 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.655 |
| Excess Kurtosis | -0.57 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 44.874 |
| Revenue per Share | 0.141 |
| Market Cap | 5,581,100,032 |
| Forward P/E | -16.50 |
| Beta | 1.74 |
| Website | https://www.crisprtx.com |
As of Aug. 22, 2026, 2:46 a.m. EDT: Speculators are positioning for a significant upside move, evidenced by heavy call volume and open interest at strikes 65 and 70, which act as major resistance walls. There is notable new flow into calls at the 63 strike, suggesting a belief in a breakout above current levels. Conversely, put writers are establishing a defensive floor around the 45-50 range with substantial open interest, indicating a fear of a sharp decline if the rally stalls. Implied volatility is elevated for deep out-of-the-money calls, reflecting anticipation of a binary event or catalyst.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.12742114 |
| Address1 | Baarerstrasse 14 |
| All Time High | 220.2 |
| All Time Low | 11.63 |
| Ask | 67.84 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 1,762,360 |
| Average Daily Volume3 Month | 1,649,222 |
| Average Volume | 1,649,222 |
| Average Volume10Days | 1,762,360 |
| Beta | 1.738 |
| Bid | 44.5 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | 18.069 |
| City | Zug |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 57.72 |
| Current Ratio | 17.847 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 59.3699 |
| Day Low | 57.1 |
| Debt To Equity | 44.874 |
| Earnings Timestamp | 1,785,787,200 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -513,174,016 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.796 |
| Enterprise To Revenue | 298.723 |
| Enterprise Value | 4,000,495,872 |
| Eps Current Year | -4.44653 |
| Eps Forward | -3.49732 |
| Eps Trailing Twelve Months | -4.58 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 53.4069 |
| Fifty Day Average Change | 4.3131027 |
| Fifty Day Average Change Percent | 0.08075928 |
| Fifty Two Week Change Percent | 12.742114 |
| Fifty Two Week High | 78.48 |
| Fifty Two Week High Change | -20.760002 |
| Fifty Two Week High Change Percent | -0.264526 |
| Fifty Two Week Low | 44.12 |
| Fifty Two Week Low Change | 13.600002 |
| Fifty Two Week Low Change Percent | 0.30825028 |
| Fifty Two Week Range | 44.12 - 78.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,476,883,800,000 |
| Float Shares | 96,273,974 |
| Forward Eps | -3.49732 |
| Forward P E | -16.504066 |
| Free Cashflow | -215,845,872 |
| Full Exchange Name | NasdaqGM |
| Fullday Change | -1.65 |
| Fullday Change Percent | -2.77918 |
| Fullday Price | 57.5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -461,800,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0589 |
| Held Percent Institutions | 0.77801 |
| Implied Shares Outstanding | 96,692,653 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. |
| Long Name | CRISPR Therapeutics AG |
| Market | us_market |
| Market Cap | 5,581,100,032 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_262549448 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -451,139,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,740,642,808 |
| Number Of Analyst Opinions | 18 |
| Open | 58.1 |
| Operating Cashflow | -369,582,016 |
| Operating Margins | -11.27551 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 41 41 561 32 77 |
| Post Market Change | -0.22000122 |
| Post Market Change Percent | -0.38115248 |
| Post Market Price | 57.5 |
| Post Market Time | 1,787,961,179 |
| Previous Close | 59.37 |
| Price Eps Current Year | -12.980909 |
| Price Hint | 2 |
| Price To Book | 3.1944213 |
| Price To Sales Trailing12 Months | 416.7488 |
| Profit Margins | 0.0 |
| Quick Ratio | 17.791 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.04545 |
| Region | US |
| Regular Market Change | -1.65 |
| Regular Market Change Percent | -2.77918 |
| Regular Market Day High | 59.3699 |
| Regular Market Day Low | 57.1 |
| Regular Market Day Range | 57.1 - 59.3699 |
| Regular Market Open | 58.1 |
| Regular Market Previous Close | 59.37 |
| Regular Market Price | 57.72 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,385,787 |
| Return On Assets | -0.14204 |
| Return On Equity | -0.26095 |
| Revenue Growth | 10.414 |
| Revenue Per Share | 0.141 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 96,692,653 |
| Shares Percent Shares Out | 0.19389999 |
| Shares Short | 18,744,855 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 19,808,194 |
| Short Name | CRISPR Therapeutics AG |
| Short Percent Of Float | 0.222 |
| Short Ratio | 12.77 |
| Source Interval | 15 |
| Symbol | CRSP |
| Target High Price | 291.0 |
| Target Low Price | 44.0 |
| Target Mean Price | 87.55556 |
| Target Median Price | 80.0 |
| Total Cash | 2,364,352,000 |
| Total Cash Per Share | 24.452 |
| Total Debt | 783,747,968 |
| Total Revenue | 13,392,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 53.1398 |
| Two Hundred Day Average Change | 4.5802 |
| Two Hundred Day Average Change Percent | 0.08619152 |
| Type Disp | Equity |
| Volume | 1,385,787 |
| Website | https://www.crisprtx.com |
| Zip | 6,300 |